{"retracted":true,"timestamp":1301616000000,"update":{"timestamp":null,"doi":null,"pmid":25932678,"type":"retraction"},"doi":"10.1172/JCI44325","journal":"The Journal of clinical investigation","publisher":null,"title":"FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer."}
